Swiss biotech startup Hedera Dx raises €14 million in its mission to improve cancer treatment options

Published on September 21, 2022

Lausanne-headquartered Hedera Dx is pioneering the adoption of liquid biopsy in cancer treatments. The biotech startup has just raised €14 million to push forward its mission of bringing better access to cutting-edge treatments to patients around the world. Cancer. One of the world’s most prevalent and devastating illnesses, it’s reported that 1 in 3 people…

This content is for members only. Visit the site and log in/register to read.

The post Swiss biotech startup Hedera Dx raises €14 million in its mission to improve cancer treatment options appeared first on EU-Startups.

Continue reading on website
Other news

Zurich-based Ledgy secures €22 million to encourage a culture of ownership through the power of equity

September 21, 2022
Zurich-based Ledgy has been encouraging a culture of ownership across Europe’s business landscape since 2017. Now, the startup has just picked up €22 million to fuel the expansion of its platform.  Retaining and attracting top talent has become one of the biggest challenges HR teams have to overcome in recent years. For startups in particular,… This content is for members only. Visit the site and

CAN-AM Stories – Entrepreneurship Across the Border: Dr. Céline Leheurteux

September 21, 2022
In partnership with The U.S. Embassy in Canada, Startup Canada is celebrating and spotlighting women’s entrepreneurship across the border – speaking to leading founders to learn more about their journeys, and the vital role of cross-border collaboration on their entrepreneurial successes. Startup Canada was pleased to sit down with Dr. Céline Leheurteux, Canadian founder and innovator in the veter